Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 8/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13098136 | 0.89 | ALOX15 (0.66) | ALOX15HSD17B10CMA1AHRTRPA1 | |
| SCHEMBL2988989 | 0.88 | ALOX15 (0.63) | ALOX15HSD17B10CMA1AHRTRPA1 | |
| SCHEMBL14084570 | 0.83 | ALOX15 (0.52) | ALOX15HSD17B10CMA1AHRTRPA1 | |
| SCHEMBL31546300 | 0.81 | ALOX15 (1.00) | ALOX15HSD17B10AHRPNMTGAA | |
| SCHEMBL2087881 | 0.81 | ALOX15 (1.00) | ALOX15HSD17B10AHRPNMTGAA | |
| SCHEMBL11111017 | 0.79 | ALOX15 (0.67) | ALOX15HSD17B10CMA1AHRPNMT | |
| SCHEMBL7866841 | 0.79 | ALOX15 (0.67) | ALOX15HSD17B10AHRGAANPSR1 | |
| SCHEMBL18350153 | 0.79 | TRPA1 (0.52) | CMA1AHRTRPA1PNMTADRA2A | |
| SCHEMBL15373652 | 0.77 | PNMT (0.45) | ALOX15HSD17B10CMA1AHRPNMT | |
| SCHEMBL13833021 | 0.77 | BRD4 (0.49) | ALOX15HSD17B10CMA1AHRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-8461145-B2 | Dibenzoazepine and dibenzooxazepine TRPA1 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-8461145-B2 | Dibenzoazepine and dibenzooxazepine TRPA1 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20110124666-A1 | 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS | Janssen Pharmaceutica NV a corporation | 2011-05-26 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| US-20100273773-A1 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | US | disclosed |
| WO-2009147079-A1 | 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009071631-A2 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124666-A1 | 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV3 | ALOX15 710/4885HSD17B10 3134/4885CMA1 3414/4885 |
| US-20100273773-A1 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | TRPA1, TRPV1, TRPV2 | ALOX15 83/4885HSD17B10 1768/4885CMA1 1227/4885 |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | ALOX15 398/4885HSD17B10 3348/4885CMA1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.